Highlights From the AASLD/EASL ALD Endpoints Conference 2019
Madeline Bertha, Haripriya Maddur – 30 June 2020
Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine
George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim – 30 June 2020
Cholangitis Lenta: What Hepatologists Need to Know
Adam L. Booth, Shehzad N. Merwat, Sheharyar K. Merwat, Heather L. Stevenson – 30 June 2020
Cause for Confusion: Noncirrhotic Hyperammonemic Encephalopathy
Avash Kalra, J. P. Norvell – 30 June 2020
Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine
George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim – 30 June 2020
Fatal COVID‐19 in a Patient with End‐Stage Liver Disease Wait‐Listed for Liver Transplantation: An Evidence‐Based Review of COVID‐19 Screening Modalities Prior to Transplant
Yoona Rhee, Edie L. Chan, Sheila L. Eswaran, Costica Aloman, Martin Hertl, Carlos A.Q. Santos – 30 June 2020
It Is Not All About Pretransplant Factors: Posttransplant Complications Alter the Risk of Alcohol Relapse
Toshihiro Kitajima, Shunji Nagai, Dilip Moonka, Antu Segal, Marwan S. Abouljoud – 30 June 2020
Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial
Khurram Bari, Shimul A. Shah, Tiffany E. Kaiser, Robert M. Cohen, Nadeem Anwar, David Kleesattel, Kenneth E. Sherman – 30 June 2020 – Despite adverse effects like hyperglycemia, new‐onset diabetes after transplant (NODAT), and infectious complications, corticosteroid use remains an important part of liver transplantation (LT) immune suppression. Budesonide, a synthetic corticosteroid, undergoes extensive first‐pass hepatic metabolism with only 10% systemic bioavailability, providing an opportunity for an improved toxicity‐therapeutic ratio.
Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis
Marie Irlès‐Depé, Stéphanie Roullet, Martine Neau‐Cransac, Jérôme Dumortier, Sébastien Dharancy, Pauline Houssel‐Debry, Olivier Boillot, Laurence Chiche, Christophe Laurent, David Laharie, Victor De Lédinghen – 30 June 2020 – Approximately 80% of patients with primary sclerosing cholangitis (PSC) also have inflammatory bowel disease (IBD), and its effect on the outcomes of liver transplantation (LT) for PSC is unclear. We retrospectively collected data from adults who underwent LT for PSC from 1989 to January 2018 in 4 French LT centers.
Reproductive Health and Nonalcoholic Fatty Liver Disease in Women: Considerations Across the Reproductive Lifespan
Monika Sarkar, Ayako Suzuki – 30 June 2020